Quote:

---

The FDA approved Trodelvy based on the results of a clinical trial of 108 patients with metastatic triple-negative breast cancer who had received at least two prior treatments for metastatic disease.

---

So our numbers are from patients who failed FOUR lines of treatment, while Trodelvy patients *may* have only failed TWO. (Edit: or THREE — we crossed posts, Ohm.)

Curiouser and curiouser. If I was BP, I’d want to own Leronlimab yesterday.